Sagimet Biosciences Inc. (NASDAQ: SGMT)
$4.8500
-0.5200 ( -8.32% ) 793.2K
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
Market Data
Open
$4.8500
Previous close
$5.3700
Volume
793.2K
Market cap
$157.44M
Day range
$4.7710 - $5.4050
52 week range
$2.3900 - $20.7100
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 4 | Insider transactions | 1 | Jun 07, 2024 |
| 8-k | 8K-related | 15 | Jun 06, 2024 |
| 8-k | 8K-related | 47 | May 23, 2024 |
| 8-k | 8K-related | 15 | May 15, 2024 |
| 10-q | Quarterly Reports | 54 | May 15, 2024 |
| 4 | Insider transactions | 1 | May 08, 2024 |
| 3 | Insider transactions | 2 | May 08, 2024 |
| 8-k | 8K-related | 13 | May 06, 2024 |
| ars | Annual reports | 1 | Apr 18, 2024 |
| def | Proxies and info statements | 9 | Apr 18, 2024 |